01.002 RWE KR JULY 2022 B 28-07-2022

Use of real-world evidence to create standardised treatment pathways is essential for the future of oncology

  • “A truly high-value drug is the one that costs the least and has the most benefit for our patients”
  • “What we need is more research focusing on value-based pricing, rigorous post-approval follow-up for efficacy and toxicity, and use of real world evidence in the creation of standardized treatment pathways.”

 Devika Das, MBBS, Clinical Assistant Professor of Hematology and Oncology

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at